The two drugs, vopimetostat from Tango Therapeutics and daraxonrasib from Revolution Medicines, will now be tested in a Phase 3 trial.
Revolution Medicines’ experimental pancreatic cancer drug has been the star of the oncology field in recent weeks, with new data showing the medicine produced unprecedented outcomes for patients.
Its next act — this time as a co-lead — was revealed M... [267 chars]